[1] 黄循铷, 王承党, 王瑞幸, 等. 溃疡性结肠炎小鼠肠道通透性改变与TNF-α及NF-KB p65的关系[J]. 中国应用生理学杂志, 2016, 32(2):112-115. [2] Matsuno H, Yudoh K, Katayama R, et al. The role of TNF-α in the pathogenesis of infammation and joint destruction in rheumatoid arthritis(RA):a study using a human RA/SCID mouse chimera[J]. Rheumatology, 2002, 41(3):329-337. [3] 张洁, 孙红英, 江怡雯, 等. NF-κB在Sjogren's综合征中的表达及意义. 中国临床医学, 2006, 13(2):300-301. [4] 唐惠玲. NF-κB信号传导与疾病研究进展[J]. 黑龙江医药科学, 2012, 35(5):34-36. [5] Sughra K, Birbach A, de Martin R, et al. Interaction of the TNFR-receptor associated factor TRAF1 with I-kappa B kinase-2 and TRAF2 indicates a regulatory function for NF-kappa B signaling[J]. PLoS One, 2010, 5(9):e12683. [6] Li X, Commane M, Nie H, et al. Act1,an NF-kappa B-activating protein[J]. Proc Natl Acad Sci U S A, 2000, 97(19):10489-10493. [7] 依那西普治疗类风湿关节炎和强直性脊柱炎专家组.依那西普治疗类风湿关节炎和强直性脊柱炎的专家建议(2013)[J]. 中华医学杂志, 2013, 93(18):1363-1369. [8] 高晓王君, 解骏, 肖涟波, 等. TNF-α拮抗剂对胶原诱导大鼠类风湿关节炎骨破坏治疗作用的实验研究[J]. 中国骨质疏松杂志, 2013, 19(5):458-464. [9] 贾峰峰, 张进, 刘晓宇, 等. 依那西普对炎性疼痛大鼠的疼痛症状及肿瘤坏死因子-α表达的影响[J]. 山西医药杂志, 2014, 43(22):2611-2613. [10] Takeshita M, Suzuki K, Kikuchi J, et al. Infliximab and etanercept have distinct actions but similar effects on cytokine profiles in rheumatoid arthritis. Cytokine, 2015, 75(2):222-227. [11] 梁春祥, 陈克冰, 马伟英, 等. TNF-α拮抗剂(Etanercept)治疗脊髓损伤作用机制的实验研究[J]. 中国骨与关节损伤杂志, 2013, 28(7):647-649. [12] Fautrel B, Pham T, Alfaiate T, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission:results of the multicentre non-inferiority randomised open-label controlled trial (STRASS:Spacing of TNF-blocker injections in rheumatoid arthritis study)[J]. Ann Rheum Dis, 2016, 75(1):59-67. [13] Moots RJ, Mays R, Stephens J, et al. Burden of dose escalation with tumour necrosis factor inhibitors in rheumatoid arthritis:a systematic review of frequency and costs[J]. Clin Exp Rheumatol, 2015, 33(5):737-745. |